Black Diamond Therapeutics Inc
BDTX
查看详细走势图
2.600USD
+0.060+2.36%
收盘 12/22, 16:00（美东）报价延迟15分钟
148.05M总市值
6.86市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.36%
5天
-1.89%
1月
-31.58%
6月
+11.59%
今年开始到现在
+21.50%
1年
+17.12%
查看详细走势图
TradingKey Black Diamond Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Black Diamond Therapeutics Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名25/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.25。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Black Diamond Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
9.250
目标均价
+236.36%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Black Diamond Therapeutics Inc亮点
亮点风险
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Black Diamond Therapeutics Inc简介
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
公司代码BDTX
公司Black Diamond Therapeutics Inc
CEOVelleca (Mark A)
网址https://www.blackdiamondtherapeutics.com/
常见问题
Black Diamond Therapeutics Inc(BDTX)的当前股价是多少？
Black Diamond Therapeutics Inc(BDTX)的当前股价是 2.600。
Black Diamond Therapeutics Inc的股票代码是什么？
Black Diamond Therapeutics Inc的股票代码是BDTX。
Black Diamond Therapeutics Inc股票的52周最高点是多少？
Black Diamond Therapeutics Inc股票的52周最高点是4.940。
Black Diamond Therapeutics Inc股票的52周最低点是多少？
Black Diamond Therapeutics Inc股票的52周最低点是1.195。
Black Diamond Therapeutics Inc的市值是多少？
Black Diamond Therapeutics Inc的市值是148.05M。
Black Diamond Therapeutics Inc的净利润是多少？
Black Diamond Therapeutics Inc的净利润为-69.68M。
现在Black Diamond Therapeutics Inc(BDTX)的股票是买入、持有还是卖出？
根据分析师评级，Black Diamond Therapeutics Inc(BDTX)的总体评级为买入，目标价格为9.250。
Black Diamond Therapeutics Inc(BDTX)股票的每股收益（EPS TTM）是多少
Black Diamond Therapeutics Inc(BDTX)股票的每股收益（EPS TTM）是0.379。
相关品种
